Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies
- 11 June 2004
- journal article
- research article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 20 (8) , 1235-1243
Abstract
SUMMARYBackground: Asians are thought to be more responsive to the lipid-lowering effects of statins than non-Asians although there are no head-to-head trials that examine this perception.Objective: To compare the results of the GOALLS and STATT studies that used similar titrate-to-goal protocols with 20 mg up to 80 mg simvastatin in Asian and non-Asian coronary heart disease (CHD) patients.Methods: GOALLS (N = 198; included non-Asians and Asians) and STATT (N = 133; included Asians only) were both multi-center, open-label 14-week studies in CHD patients with serum low density lipoprotein cholesterol (LDL-C) levels 115 mg/dL–180 mg/dL and triglycerides (TG) levels ≤ 400 mg/dL. Simvastatin was titrated from 20 mg/day up to 80 mg/day in order to achieve the National Cholesterol Education Program (NCEP) LDL-C target ≤ 100 mg/dL. The primary efficacy variable was the percentage of patients attaining the NCEP LDL-C target at Week 14. Secondary endpoints included proportion of patients achieving the European So...Keywords
This publication has 8 references indexed in Scilit:
- Sustained Reduction of Serum Cholesterol in Low-Dose 6-Year Simvastatin Treatment With Minimum Side Effects in 51,321 Japanese Hypercholesterolemic PatientsCirculation Journal, 2003
- Effects of Low‐Dose Pravastatin on Plasma Levels of Lipids and Apolipoproteins in Japanese Type II Hyperlipoproteinemic Subjects with Apolipoprotein E Phenotype E3/2, E3/3, and E4/3The Journal of Clinical Pharmacology, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Attaining United States and European Guideline LDL-cholesterol Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study)Current Medical Research and Opinion, 2000
- Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2Atherosclerosis, 1998
- Inter‐ethnic comparisons of the pharmacokinetics of the HMG‐CoA reductase inhibitor cerivastatinBritish Journal of Clinical Pharmacology, 1998
- A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemiaThe American Journal of Cardiology, 1997
- Comparative Efficacy and Tolerability of 5 and 10 mg Simvastatin and 10 mg Pravastatin in Moderate Primary HypercholesterolemiaCardiology, 1994